Acute exacerbation of idiopathic pulmonary fibrosis triggered by Aspergillus empyema. (2018)

• Record Type: Journal Article
• Authors: Suzuki, Atsushi; Kimura, Tomoki; Kataoka, Kensuke; Matsuda, Toshiaki; Yokoyama, Toshiki; Mori, Yuta; Kondoh, Yasuhiro
• Is Part Of: Respiratory medicine case reports. Volume 23(2018)
• Page Start: 103
• Page End: 106
• Publication Date: 2018
• Subjects: Idiopathic pulmonary fibrosis -- Acute exacerbation -- AE-IPF -- Triggered AE -- Aspergillus infection; AE acute exacerbation -- AMPH-B amphotericin-B -- CRP C-reactive protein -- CT computed tomography -- ILD interstitial lung disease -- IPF idiopathic pulmonary fibrosis -- rhTM recombinant human soluble thrombomodulin -- VRCZ voriconazole -- WBC white blood cell; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2018.01.004
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: Acute exacerbation (AE) is a severe and life-threatening complication of idiopathic pulmonary fibrosis (IPF). In 2016, the definition and diagnostic criteria for AE-IPF were updated by an international working group. The new definition includes any acute, clinically significant respiratory deterioration (both idiopathic and triggered events) characterized by evidence of new widespread alveolar abnormality in patients with IPF. There are no currently proven beneficial management strategies for idiopathic and triggered AE-IPF. This is the first report describing AE-IPF triggered by Aspergillus empyema, which was improved by a combination of corticosteroid, systemic antifungal therapy, local antifungal therapy, and additional pharmacological therapies. Future research may reveal optimal strategies for both idiopathic and triggered AE-IPF.